Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$27.15 – $37.78
5% from low
No one on the platform currently holds GLPG.
No tracked institution reports a position in GLPG as of their last filing.
No one on the platform has traded GLPG yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $27M | -90.0% | $-3.01 | $-7.04–$-0.78 | — | 3 |
| 2027 | $42M | +53.3% | $-2.26 | $-4.93–$0.43 | — | 3 |
| 2028 | $21M | -50.9% | $-2.81 | $-3.56–$-1.95 | — | 1 |
| 2029 | $35M | +68.4% | $-2.10 | $-2.66–$-1.46 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-06 | $-1.27 | $0.25 | +119.7% |
| 2026-02-23 | $1.00 | $16.38 | +1538.0% |
| 2025-11-05 | $-0.20 | $-3.59 | -1696.4% |
| 2025-07-23 | $-0.67 | $-1.89 | -182.3% |
| 2025-04-23 | $-0.23 | $-2.47 | -973.9% |
| 2025-02-28 | $-0.24 | $0.39 | +263.3% |
| 2024-10-30 | $-0.27 | $-0.77 | -185.2% |
| 2024-08-01 | $-0.04 |
| $0.14 |
| +450.0% |
| $28M |
| — |
| NXTCNextCure, Inc. | $8.28 | +1.35% | $30M | — |
| RAREUltragenyx Pharmaceutical Inc. | $26.38 | -1.79% | $2.6B | — |
Source: Financial Modeling Prep · peers by sector/industry